tbuckley/cabot-search huggingface dataset:
Archives of Internal Medicine, Chicago
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bullet embolism from the head to the heart
Authors: C. A. Hiebert
Journal: JAMA (1974)

A bullet entered the cranial vault of a boy and migrated via the transverse venous sinus to the opposite side of the skull and thence via the great veins to the right ventricle. Emergency craniotomy arrested hemorrhage, and 19 days later, the bullet was retrieved by open cardiotomy. Its location astride the left anterior descending coronary artery illustrates that removal of an apparently trivial foreign body from the heart is occasionally justified. (<i>JAMA</i>229:442-443, 1974)
Keyword Index – Volumes 69+70
Journal: Cardiovascular Research (2006)

ABCA1 (69) 527 Abdominal aortic aneurysm (70) 158 Acute inflammation (69) 459 Acute myocardial infarction (70) 297 ADAMs (69) 574 Adenosine (70) 212 Adenosine receptors (70) 308 Adhesion molecules (69) 341 Adrenaline (69) 128 h-Adrenergic (69) 370, (70) 97 Adrenergic agonists (69) 816 Adrenergic receptors (69) 46 h 1 -and h 2 -adrenoceptors (69) 128 Adrenomedullin (70) 158 Age (70) 97 Akt (69) 502, (70) 530 Allograft rejection (69) 289 Angiogenesis (69) 207, (69) 512, (69) 788, (69) 845, (69) 925, (70) 126, (70) 146, (70) 446 Angiotensin (69) 432 Angiotensin II (69) 66 Antiarrhythmic agents (69) 865 Antiarrhythmic drug (70) 486 AP-1 (69) 66 Apoptosis (69) 15, (69) 57, (69) 614, (69) 697, (69) 908, (70) 325, (70) 457, (70) 578 Apurinic/apyrimidinic endonuclease1/redox factor-1 (69) 520 Arrhythmia (mechanism) (70) 88 Arrhythmia (mechanisms) (69) 86, (69) 865 Arterial fibrosis (69) 764 Artery (69) 272 Atherosclerosis (69) 76, (69) 280, (69) 341, (69) 527, (69) 585, (69) 595, (69) 625, (69) 706, (69) 755, (70) 42, (70) 61, (70) 446 Atomic force microscopy (69) 916 Atrial fibrillation (70) 486, (70) 497 Atrial function (70) 88 Atrial natriuretic peptide (69) 318 Attrition (69) 677 Autocrine (70) 97 Autonomic imbalance (70) 434 Autonomic nervous system (70) 12 Autoregulation (70) 475 AV-node (69) 412 Baroreflex (70) 12 Blood flow (69) 245, (69) 925 Blood pressure (70) 12 BMP (69) 15 Bone marrow (69) 476, (70) 50 Bone marrow-derived stem cells (70) 117 Bradykinin (70) 212 Brain natriuretic peptide (69) 318 Brugada syndrome (70) 521 Ca oscillations (69) 825 Ca 2+ (69) 140, (70) 475 Ca 2+ sensitivity (69) 370 Ca 2+ transients (70) 509 Ca 2+ -sensitivity (70) 79 Ca-channel (69) 391, (69) 816, (69) 855 Cadherins (69) 614 Calcitonin gene-related peptide (CGRP) (70) 589 Calcium (69) 164, (69) 816, (69) 908, (70) 346, (70) 364 Calcium channel (69) 798 Calpain (69) 697, (70) 274 Carbon monoxide (70) 231 Cardiac electrophysiology (69) 381 Cardiac hypertrophy (70) 422 Cardiac myocytes (69) 788 Cardiac remodeling (69) 574 Cardiac repair (69) 476 Cardiac transplant (70) 222 Cardiac transplantation (69) 272 Cardiomyocyte (70) 117 Cardiomyocytes (69) 423, (70) 286, (70) 346 Cardiomyopathy (69) 26, (69) 466, (69) 888, (70) 410, (70) 566 Cardioprotection (69) 459, (70) 231, (70) 297 Cardioprotective (69) 318 Cardiovascular disease (69) 636 Cariporide (69) 916 Carotid injury (69) 253 Carvedilol (69) 128 Caspase-12 (69) 908 Catalase (69) 440 Caveolae (69) 798, (69) 816, (69) 825, (70) 31, (70) 42 Caveolin (69) 788, (70) 42 CD36 (69) 527 Cell communication (69) 236 Cell culture (69) 381, (70) 286 Cell death (69) 440, (70) 191, (70) 364 Cell differentiation (70) 126 Cell proliferation (70) 146 cGMP (70) 274 Chemical preconditioning (70) 384 Chlamydia pneumoniae (69) 280 Cholinergic (70) 97 Chronic heart failure (70) 434
VD Incidence Rising In Europe
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of relapse-free survival in T3N0 colon cancer: The role of chemotherapy—A multicentric retrospective analysis.
Authors: Roberta Grande, Maurizio Cosimelli, Donatello Gemma, Fabrizio Ciancola, Domenico C. Corsi, Lorena Rossi, Isabella Sperduti, Maria Agnese Fabbri, Raffaello Mancini, Enzo Ruggeri, Germano Zampa, Sara Bianchetti, Teresa Gamucci
Journal: Journal of Clinical Oncology (2012)

578 Background: Use of adjuvant chemotherapy (AC) in stage II colon cancer (CC) is still under debate. Choice should be based on patients (pts) and disease characteristics. According to worldwide guidelines AC should be considered in high-risk (H) T3N0 pts. No data are available for better option in low-risk (L) pts. Aim of the study is to evaluate relapse-free survival (RFS) and disease-free survival (DFS) retrospectively in T3N0 CC pts related to treatment. Methods: RFS and DFS are evaluated with Kaplan Meier method. In order to find the optimal cut off for node number the receiver operating characteristics curve analysis and maximally selected rank statistics were performed. Multivariate Cox proportional hazard model was developed using stepwise regression, enter limit and remove limit were p = 0.10 and p = 0.15 respectively. Results: 1,000 pts with T3N0 CC were recruited. To date, data of 764 pts are available. Median age was 68 (29-93), M/F 42/344, grading 1/2/3 40/561/132; 303 L (40%), 356 H (46%), 105 unknown (14%); 121 (16%) pts showed symptoms (S) at diagnosis: 43 pts had perforation (P) or bowel obstruction (BO). Median sampled lymph nodes (LN) were 15 (1-76); 339 (44%) pts were treated with AC. Median follow up (fu) was 5 years (yr) (range 3-24). Survival analysis analysis was performed only for pts with a minimum fu of 3 yr and younger than 80 (79%). 5 yr RFS was 79% and 5 yr DFS was 77%. At multivariate analysis S, LN and AC were prognostic factors for RFS. AC is prognostic factor for all endpoints (Table). In L group 5 yr RFS was 88% in treated pts and 71% in non-treated pts (p 0.004); in H group was respectively 84% and 70% (p 0.002). Conclusions: Preliminary data confirmed the role of known prognostic factors and suggest the relevance of AC also in L stage II T3N0 CC pts. However, the highest risk in L subgroup should be identified to be submitted to AC. Data collection is ongoing. [Table: see text]
具有非苍白性发红的人患压力性溃疡的风险较高
Authors: C. Shi, L.J. Bonnett, J.C. Dumville, N. Cullum
Journal: British Journal of Dermatology (2020)

压力性溃疡,也称为褥疮,是主要由长时间的压力引起的皮肤损害,例如卧床不起的人中发生的褥疮。在英国、美国和加拿大的医院中,每 10,000 例患者中有 470 至 3,210 例发生压力性溃疡。其严重程度分级为 1 期(最不严重)至 4 期(最严重)。 对于患者和护理人员来说,重要的是要知道正常皮肤是什么样子,并定期检查可能出现压力性溃疡的常见部位(例如,臀部、脚跟和下背部)的皮肤变化。 非苍白性发红(按下后不会变白的皮肤发红)是重要的皮肤变化。这项研究由曼彻斯特大学和英国利物浦大学的研究人员开展,旨在查明具有非苍白性发红的人将来是否比没有非苍白性发红的人更容易患压力性溃疡。 作者使用系统性综述和个人水平数据分析方法总结了十三项研究(68,077 人)的证据,并分析了 3,223 例患者的个人水平数据。他们的分析表明,具有非苍白性发红的人在 28 天之内出现新的 2 期或以上压力性溃疡的比率是无非苍白性发红的人的 2.72 倍。 这意味着,如果每 1,000 名无非苍白性发红的人中有 73 人在 28 天内出现新的 2 期及以上压力性溃疡,那么每 1,000 名有非苍白性发红的人中就可能有 176 人会出现新的溃疡。 作者得出的结论是,与无非苍白性发红的人相比,具有非苍白性发红的人在 28 天之内更容易发生 2 期或以上的新的压力性溃疡。对于医务人员而言,重要的是识别出非苍白性发红并进行适当干预以预防压力性溃疡。 本摘要涉及研究: 非苍白性发红预测压力性溃疡的发生: 一项系统综述以及个体参加者数据的荟萃分析
National Health Insurance. Third Annual Report of the Medical Research Committee, 1916-1917.
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human papillomavirus type 16 DNA in periungual squamous cell carcinomas
Authors: R. L. Moy
Journal: JAMA (1989)

Ten squamous cell carcinomas (in situ or invasive) of the fingernail region were analyzed for the presence of DNA sequences homologous to human papillomavirus (HPV) by dot blot hybridization. In most patients, the lesions were verrucae of long-term duration that were refractory to conventional treatment methods. Eight of the lesions contained HPV DNA sequences, and in six of these the sequences were related to HPV 16 as deduced from low-stringency nucleic acid hybridization followed by low- and high-stringency washes. Furthermore, the restriction endonuclease digestion pattern of DNA isolated from four of these lesions was diagnostic of episomal HPV 16. The high-frequency association of HPV 16 with periungual squamous cell carcinoma is similar to that reported for HPV 16 with squamous cell carcinomas on mucous membranes at other sites, notably the genital tract. Our findings suggest that HPV 16 may play an important role in the development of squamous cell carcinomas of the finger, most notably those lesions that are chronic and located in the periungual area. (<i>JAMA</i>. 1989;261:2669-2673)
Protective Effects of N-acetylcysteine Treatment after Phosgene Exposure in Rabbits
Authors: Alfred M. Sciuto, Paul T. Strickland, Thomas P. Kennedy, Gail H. Gurtner
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

We examined the effects of treatment with N-acetylcysteine (NAC) on pulmonary edema formation in isolated perfused rabbit lungs following in vivo phosgene exposure. This study focused on posttreatment intratracheal administration of NAC after exposure. Rabbits, 2 to 3 kg, were exposed to a cumulative dose of phosgene to attain a concentration × time exposure effect of 1,500 ppm/min. Lungs were perfused with Krebs-Henseleit buffer at 40 ml/min from 70 to 150 min after exposure. Pulmonary artery pressure (Ppa), tracheal pressure (Pt), and the rate of lung weight gain (LWG) were measured continuously. Perfusate concentration of peptide leukotrienes LTC4, D4, and E4 were measured every 20 min during perfusion. At the conclusion of the experiment, lung tissue was analyzed for reduced and oxidized glutathione (GSH and GSSG) and lipid peroxidation (thiobarbituric acid-reactive substances, TBARS). Exposure to phosgene significantly increased Pt, LWG, LTC4, D4, and E4, TBARS, and GSSG over time compared with controls. Compared with phosgene, intratracheal NAC lowered Ppa, LWG, LTC4, D4, and E4, TBARS, and GSSG. We conclude that NAC protected against phosgene-induced lung injury by acting as an antioxidant by maintaining protective levels of glutathione, reducing both lipid peroxidation and production of arachidonic acid metabolites.
New Regulation Requires Imprinting on Solid Oral Dosage Form Drug Products
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 533: The immune landscape in colon cancer and its changes after radiotherapy
Authors: Cristiana Lo Nigro, Dario Sangiolo, Vincenzo Ricci, Ornella Garrone, Andrea Abbona, Antonella Falletta, Anna Merlotti, Chiara Varamo, Massimo Aglietta, Loretta Gammaitoni, Oscar Bertetto, Marco Merlano
Journal: Cancer Research (2019)

Abstract Background: The TRANSLATE project started in 2016 to test the immune effects on circulating immune cells and cytokines of metronomic Cyclophosphamide (CTX), daily low-dose IL-2 administered every other week, and radiotherapy (RT). The rationale is based on self vaccination induced by RT, T cells expansion by IL-2 treatment and selective Tregs down regulation by low dose cyclophosphamide administration. Materials/Methods: Treatment consisted of CTX 50/mg tab daily continuously until progression or unacceptable toxicity, 8 Gy single fraction on one metastatic lesion given day 8 from CTX start and IL-2, 500.000 UI twice a day i.v. day 1 to 5 every other week, starting the day after RT. We enrolled patients with end-stage for colon, breast, kidney and prostate cancer. Analysis was performed at baseline, the day after RT, after 28 days from treatment start and at disease progression. Assay focused on Tregs, CD8+, NK, MDSC, CD3-PD1, IL-2, IL-4, IL-5, IL- 6, IL-10, IL-12, IL-13, IL-17a, TNFα, IFNγ, TGFβ. We report baseline and post-RT data separately in patients with colon cancer (CC) and other patients (non-CC). Results: We report data from 8 pts with left colon, 6 with breast, 2 with kidney and 3 with prostate cancer. At baseline, cytokine expression was similar in CC and non-CC except IFNγ and IL-13, both less represented in CC. After RT, TNFα increased in both groups, but more evidently in CC. A clear increase in IL-10 and IFNγ occurred only in non-CC, while IL-2 increased only in CC. Cumulatively, CC and non-CC reacted differently to RT in terms of positive or negative changes of the analyzed cytokines. On the contrary, we did not observe clear differences in immune cells between CC and non-CC neither at baseline nor after RT. Discussion: The limited number of patients reduced the interpretation of the study. The differences observed are numerical, but not statistically significant. Colon cancer shows some peculiarities, including the low IL-13 and IFNγ value and a different response to RT. Further analyses investigations are in progress. Citation Format: Cristiana Lo Nigro, Dario Sangiolo, Vincenzo Ricci, Ornella Garrone, Andrea Abbona, Antonella Falletta, Anna Merlotti, Chiara Varamo, Massimo Aglietta, Loretta Gammaitoni, Oscar Bertetto, Marco Merlano. The immune landscape in colon cancer and its changes after radiotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 533.
Chromogranin A
Authors: Lewis Landsberg
Journal: New England Journal of Medicine (1984)

Mammalian adrenal medullary tissue is composed of endocrine secretory units called chromaffin cells. These cells synthesize and store catecholamines and release them in response to neural impulses carried in the splanchnic nerves. The designation "chromaffin," which implies an affinity for chrome, is derived from histopathology and refers to a characteristic darkening that occurs when tissues rich in chromaffin cells are exposed to aqueous solutions of potassium dichromate. It is now recognized that this peculiar darkening is caused by oxidation of the large quantities of catecholamines contained within the chromaffin cells and by the subsequent polymerization of the oxidized catecholamine derivatives . . .
Citations
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Civil Rights and Medicare
Authors: W. H. Stewart
Journal: JAMA (1966)

On July 1, the great majority of American hospitals will be qualified for participation in Medicare—qualified on the basis of health-care standards (which are similar to those of the Joint Commission of the Accreditation of Hospitals) and qualified also under Title VI of the Civil Rights Act. The physician can be of enormous help in the next several weeks in seeing to it that the hospitals in his community are numbered among these qualified institutions. Title VI prohibits discrimination on the basis of race, color, or national origin in any institution receiving financial aid from the US government. It applies not only to Medicare but to some 50 other federal programs which at the present time extend aid or support to hospitals, including the Hill-Burton program, other grant programs administered by the Public Health Service, and other programs administered by the federal government. The Public Health Service has issued and
A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients
Authors: O. Boyd
Journal: JAMA (1993)

<h3>Objective.</h3> —To assess the effect of deliberate perioperative increase in oxygen delivery on mortality and morbidity in patients who are at high risk of both following surgery. <h3>Design.</h3> —Prospective, randomized clinical trial. <h3>Setting.</h3> —A teaching hospital general intensive care unit, London, England. <h3>Patients.</h3> —A total of 107 surgical patients, who were assessed as high risk from previously identified criteria, were studied during an 18-month period. <h3>Interventions.</h3> —Patients were randomly assigned to a control group (n=54) that received best standard perioperative care, or to a protocol group (n=53) that, in addition, had deliberate increase of oxygen delivery index to greater than 600 mL/min per square meter by use of dopexamine hydrochloride infusion. <h3>Outcome Measures.</h3> —Mortality and complications were assessed to 28 days postoperatively. <h3>Results.</h3> —Groups were similar with respect to demographics, admission criteria, operation type, and admission hemodynamic variables. Groups were treated similarly to maintain blood pressure, arterial saturation, hemoglobin concentration, and pulmonary artery occlusion pressure; however, once additional treatment with dopexamine hydrochloride had been given, the protocol group had significantly higher oxygen delivery preoperatively (median, 597 vs 399 mL/min per square meter;<i>P</i>&lt;.001) and postoperatively (<i>P</i>&lt;.001). Results indicate a 75% reduction in mortality (5.7% vs 22.2%;<i>P</i>=.015) and a halving of the mean (±SEM) number of complications per patient (0.68 [±0.16] vs 1.35 [±0.20];<i>P</i>=.008) in patients randomized to the protocol group. <h3>Conclusion.</h3> —Perioperative increase of oxygen delivery with dopexamine hydrochloride significantly reduces mortality and morbidity in high-risk surgical patients. (<i>JAMA</i>. 1993;270:2699-2707)
Biochimica et Biophysica Acta, Amsterdam
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal